MedTrace Logo

Trial of Methyl Aminolevulinate Plus Aktilite in Facial Photodamage

NCT00629317 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2009-03-16

No results posted yet for this study

Summary

The aim of the study is to determine the efficacy of MAL + Aktilite versus placebo + Aktilite in facial photodamage in a randomized double blind trial.

Conditions

  • Skin Aging

Interventions

OTHER

Moisturizer

Cetaphil cream(For 3 hours) + Aktilite ( Photodynamic Therapy for 8 minutes)

DRUG

Methyl Aminolevulinate

Methyl Aminolevulinate cream for 3 hours before Photodynamic therapy ( Aktilite)

Sponsors & Collaborators

  • Galderma R&D

    collaborator INDUSTRY

  • Universidad de Antioquia

    lead OTHER

Principal Investigators

  • Gloria Sanclemente, Dr · Coordinator Group of Investigative Dermatology-GRID

  • Hector I Garcia, Dr. · Coordinator GRAEPIC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
35 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2009-01-31
Completion
2009-03-31

Countries

  • Colombia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00629317 on ClinicalTrials.gov